Advertisement
UK markets close in 7 hours 22 minutes
  • FTSE 100

    7,956.67
    +24.69 (+0.31%)
     
  • FTSE 250

    19,782.61
    -28.05 (-0.14%)
     
  • AIM

    741.88
    -0.23 (-0.03%)
     
  • GBP/EUR

    1.1680
    +0.0011 (+0.09%)
     
  • GBP/USD

    1.2603
    -0.0035 (-0.28%)
     
  • Bitcoin GBP

    56,198.11
    +924.73 (+1.67%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,248.49
    +44.91 (+0.86%)
     
  • DOW

    39,760.08
    +477.75 (+1.22%)
     
  • CRUDE OIL

    81.84
    +0.49 (+0.60%)
     
  • GOLD FUTURES

    2,216.00
    +3.30 (+0.15%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,499.32
    +22.23 (+0.12%)
     
  • CAC 40

    8,239.73
    +34.92 (+0.43%)
     

Merck’s Inorganic Growth Strategy in 2019

Merck’s Inorganic Growth Strategy in 2019

On April 2, Merck & Co. issued a press release announcing the successful completion of its cash tender offer for Immune Design, with 86.75% of the target’s total outstanding common stock tendered on a fully diluted basis.